Evidence map›Paper›PMID 42017197›Full record

ArticleeLife2026

A quantitative in vivo CRISPR-imaging platform identifies regulators of hyperplastic and hypertrophic adipose morphology in zebrafish.

Rebecca Wafer, Panna Tandon, James Minchin

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Rebecca Wafer *Institute for Neuroscience and Cardiovascular Research, Edinburgh BioQuarter, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0009-0007-1139-3937
Panna Tandon *Institute for Neuroscience and Cardiovascular Research, Edinburgh BioQuarter, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.
James MinchinInstitute for Neuroscience and Cardiovascular Research, Edinburgh BioQuarter, College of Medicine and Veterinary Medicine, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0003-2316-1010

Funding

Biotechnology and Biological Sciences Research Council BB/X009467/1British Heart Foundation REA PhD Studentship
6 · The paper itself

Abstract

Adipose tissues exhibit a remarkable capacity to expand, regress, and remodel in response to energy status. The cellular mechanisms underlying adipose remodelling are central to metabolic health. Hypertrophic remodelling - characterised by the enlargement of existing adipocytes - is associated with insulin resistance, type 2 diabetes, and cardiovascular disease. In contrast, hyperplastic remodelling - in which new adipocytes are generated - is linked to improved metabolic outcomes. Despite its clinical importance, the regulation of hypertrophic and hyperplastic adipose morphology remains poorly understood. Here, we integrate human transcriptomic data with a quantitative CRISPR-imaging platform in zebrafish to identify regulators of adipose morphology. We developed an image-based phenotyping pipeline that captures lipid droplet size, number, and spatial patterning, and applied generalised additive modelling to quantify hyperplastic versus hypertrophic morphology signatures. Using this platform, we conducted an F0 CRISPR screen targeting 25 candidate genes and identified three that induced hypertrophic morphology (

Indexed as

Adipose TissueClustered Regularly Interspaced Short Palindromic RepeatsZebrafishAdipocytesAnimalsCRISPR-Cas SystemsHumansHyperplasiaHypertrophyZebrafish ProteinsZebrafish Proteinsadipose morphologyadipose tissueCRISPRdevelopmental biologyzebrafish

Identifiers

PMID42017197
PMCPMC13102392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.